Relationship Between Residual Plasma Viremia and the Size of HIV Proviral DNA Reservoirs in Infected Individuals Receiving Effective Antiretroviral Therapy

Overview

Journal J Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2011 Jun 2

PMID 21628667

Citations 86

Authors

Tae-Wook Chun

Danielle Murray

J Shawn Justement

Claire W Hallahan

Susan Moir

Colin Kovacs

Anthony S Fauci

Affiliations

Soon will be listed here.

Abstract

Residual plasma viremia (<50 copies/mL) persists in certain human immunodeficiency virus (HIV)-infected individuals receiving antiretroviral therapy (ART); however, the relationship between the degree of residual plasma viremia, the size of HIV reservoirs, and the level of immune activation has not been delineated. Here, we demonstrate that residual plasma viremia correlates with the size of the CD4(+) T cell viral reservoir, but not with markers of immune activation, suggesting that reactivation of the latent viral reservoir may not be the sole source of residual plasma viremia. Novel therapeutic strategies aimed at targeting the source of residual viremia may be necessary to achieve viral eradication.

Citing Articles

Managing low-level HIV viraemia in antiretroviral therapy: a systematic review and meta-analysis.

Zace D, Rindi L, Compagno M, Colagrossi L, Santoro M, Andreoni M Sex Transm Infect. 2024; 100(7):460-468.

PMID: 39288983 PMC: 11503136. DOI: 10.1136/sextrans-2024-056198.

Management of low-level HIV viremia during antiretroviral therapy: Delphi consensus statement and appraisal of the evidence.

Rindi L, Zace D, Compagno M, Colagrossi L, Santoro M, Andreoni M Sex Transm Infect. 2024; 100(7):442-449.

PMID: 39288982 PMC: 11503133. DOI: 10.1136/sextrans-2024-056199.

Learning from Persistent Viremia: Mechanisms and Implications for Clinical Care and HIV-1 Cure.

Wu F, Simonetti F Curr HIV/AIDS Rep. 2023; 20(6):428-439.

PMID: 37955826 PMC: 10719122. DOI: 10.1007/s11904-023-00674-w.

MRP8/14 Is a Molecular Signature Triggered by Dopamine in HIV Latent Myeloid Targets That Increases HIV Transcription and Distinguishes HIV+ Methamphetamine Users with Detectable CSF Viral Load and Brain Pathology.

Basova L, Lindsey A, McGovern A, Rosander A, Delorme-Walker V, ElShamy W Viruses. 2023; 15(6).

PMID: 37376663 PMC: 10304659. DOI: 10.3390/v15061363.

Impact of the first-line antiretroviral therapy on soluble markers of inflammation in cohort of human immunodeficiency virus type 1 in Moroccan patients: a prospective study.

Haddaji A, Ouladlahsen A, Lkhider M, Bensghir R, Jebbar S, Hilmi S Arch Microbiol. 2023; 205(6):223.

PMID: 37154966 DOI: 10.1007/s00203-023-03574-0.

References

Wong J, Hezareh M, Gunthard H, Havlir D, Ignacio C, Spina C . Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997; 278(5341):1291-5. DOI: 10.1126/science.278.5341.1291. View

Chun T, Stuyver L, Mizell S, Ehler L, Mican J, Baseler M . Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A. 1997; 94(24):13193-7. PMC: 24285. DOI: 10.1073/pnas.94.24.13193. View

Palmer S, Wiegand A, Maldarelli F, Bazmi H, Mican J, Polis M . New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol. 2003; 41(10):4531-6. PMC: 254331. DOI: 10.1128/JCM.41.10.4531-4536.2003. View

Yukl S, Gianella S, Sinclair E, Epling L, Li Q, Duan L . Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. J Infect Dis. 2010; 202(10):1553-61. PMC: 2997806. DOI: 10.1086/656722. View

Bailey J, Sedaghat A, Kieffer T, Brennan T, Lee P, Wind-Rotolo M . Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J Virol. 2006; 80(13):6441-57. PMC: 1488985. DOI: 10.1128/JVI.00591-06. View

Yukl S, Shergill A, McQuaid K, Gianella S, Lampiris H, Hare C . Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS. 2010; 24(16):2451-60. PMC: 2997807. DOI: 10.1097/QAD.0b013e32833ef7bb. View

Chun T, Nickle D, Justement J, Large D, Semerjian A, Curlin M . HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J Clin Invest. 2005; 115(11):3250-5. PMC: 1265878. DOI: 10.1172/JCI26197. View

Finzi D, Hermankova M, Pierson T, Carruth L, Buck C, Chaisson R . Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997; 278(5341):1295-300. DOI: 10.1126/science.278.5341.1295. View

Maldarelli F, Palmer S, King M, Wiegand A, Polis M, Mican J . ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog. 2007; 3(4):e46. PMC: 1847689. DOI: 10.1371/journal.ppat.0030046. View

10.

Buzon M, Massanella M, Llibre J, Esteve A, Dahl V, Puertas M . HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med. 2010; 16(4):460-5. DOI: 10.1038/nm.2111. View

11.

Gandhi R, Zheng L, Bosch R, Chan E, Margolis D, Read S . The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med. 2010; 7(8). PMC: 2919424. DOI: 10.1371/journal.pmed.1000321. View

12.

Dinoso J, Kim S, Wiegand A, Palmer S, Gange S, Cranmer L . Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A. 2009; 106(23):9403-8. PMC: 2685743. DOI: 10.1073/pnas.0903107106. View

13.

Walensky R, Paltiel A, Losina E, Mercincavage L, Schackman B, Sax P . The survival benefits of AIDS treatment in the United States. J Infect Dis. 2006; 194(1):11-9. DOI: 10.1086/505147. View

14.

Chun T, Nickle D, Justement J, Meyers J, Roby G, Hallahan C . Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis. 2008; 197(5):714-20. DOI: 10.1086/527324. View

15.

Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna G, Brun S . Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A. 2008; 105(10):3879-84. PMC: 2268833. DOI: 10.1073/pnas.0800050105. View